title: Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
abstract: There is a growing evidence of using Temozolomide as upfront therapy for progressive low grade gliomas. No data exist on the efficacy of nitrosoureas as an alternative to radiotherapy in those patients who progress after Temozolomide. We retrospectively reviewed 30 patients with median age of 46 years. Twenty-one patients had pure oligodendrogliomas. Thirteen patients had a non-enhancing tumor at progression after Temozolomide. The chromosomes 1p/19q were co-deleted in 5 cases and retained in 10 cases. Response rate was 10% (3 minor responses achieved in non-enhancing tumors). Tolerance was acceptable (17% grade III and IV myelosupression). Median PFS was 6.5 months. Median OS from start of salvage treatment was 23.4 months. Tumors without contrast enhancement demonstrated a better prognosis than those with contrast enhancement both in term of PFS (P = 0.0003) and OS (P = 0.0006). Chromosomes 1p/19q codeletion was not predictive for objective response to salvage treatment but correlated with a better PFS (P = 0.02). In conclusion, salvage NU chemotherapy provide disappointing results in TMZ-pretreated low grade gliomas (LGG), which should be treated in priority by conventional radiotherapy especially in LGG that display contrast enhancement at progression.
authors.affiliation: AP-HP, Université Pierre et Marie Curie UPMC, Service de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
authors.forename: Gentian
authors.initials: G
authors.lastname: Kaloshi
authors.forename: Monica
authors.initials: M
authors.lastname: Sierra del Rio
authors.forename: François
authors.initials: F
authors.lastname: Ducray
authors.forename: Dimitri
authors.initials: D
authors.lastname: Psimaras
authors.forename: Ahmed
authors.initials: A
authors.lastname: Idbaih
authors.forename: Florence
authors.initials: F
authors.lastname: Laigle-Donadey
authors.forename: Sophie
authors.initials: S
authors.lastname: Taillibert
authors.forename: Caroline
authors.initials: C
authors.lastname: Houillier
authors.forename: Caroline
authors.initials: C
authors.lastname: Dehais
authors.forename: Antonio
authors.initials: A
authors.lastname: Omuro
authors.forename: Marc
authors.initials: M
authors.lastname: Sanson
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delattre
authors.forename: Khe
authors.initials: K
authors.lastname: Hoang-Xuan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009607:Nitrosourea Compounds; D003606:Dacarbazine; D000077204:Temozolomide
references.citation: Ann Oncol. 2003 Dec;14(12):1715-21
references.pmid: 14630674
references.citation: J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
references.pmid: 9776413
references.citation: Eur J Cancer. 2006 Oct;42(15):2499-503
references.pmid: 16914310
references.citation: J Clin Oncol. 2003 Jan 15;21(2):251-5
references.pmid: 12525516
references.citation: Neurology. 2007 May 22;68(21):1831-6
references.pmid: 17515545
references.citation: Neurology. 1998 Oct;51(4):1140-5
references.pmid: 9781544
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3133-8
references.pmid: 15284265